Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06931080 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Apr 2025 to Apr 30, 2025v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Astex Pharmaceuticals
103 trials monitored
See 3 trials at risk
ADHD
387 trials monitored
See 23 trials at risk
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.
Trial Details
NCT Number NCT06931080
Lead Sponsor Otsuka Pharmaceutical Co., Ltd.
Conditions Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment 630 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov